[Effects of cepharanthin on leukopenia and thrombocytopenia induced by chemotherapy in lung cancer patients].
We studied the effects of Cepharanthin (CEP) on bone marrow suppression induced by chemotherapy in 18 primary lung cancer patients (14 NSCLC, 4 SCLC). NSCLC patients received IP (IFM+CDDP) therapy and SCLC patients received ION (IFM+VCR+ACNU) therapy. For the control, we chose the first course and we administered CEP (1 mg/kg) during the second course. The rate of leukopenia and neutropenia was significantly lower during the CEP course than during the control (p less than 0.01). The recovery rate (at 3 weeks) of leukopenia and neutropenia was significantly higher during the CEP course than during the control (p less than 0.05). But, obvious effects of CEP for lymphopenia and thrombocytopenia were not obtained. Side effects by CEP were not observed in this study. These data suggest that the large dose of CEP contributes to the prevention of leukopenia, especially neutropenia, in patients who receive a sufficient amount of anticancer drugs.
Suzuki
R
R
Dept. of Internal Medicine II, Nagoya University Hospital.
Hara
M
M
Shindoh
J
J
Matsumoto
S
S
Noda
Y
Y
Gonda
H
H
Tanaka
H
H
Taki
F
F
Takagi
K
K
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D044182:Benzylisoquinolines; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D052117:Benzodioxoles
D000470:Alkaloids; D044182:Benzylisoquinolines; C006947:cepharanthine; D052117:Benzodioxoles